MAPK1 and bronchopulmonary dysplasia: In bronchopulmonary dysplasia (BPD), WKYMVm can upregulate the phosphorylation levels of ERK, and also indirectly upregulate the levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), thereby reducing hyperoxia induced lung inflammation and lung injury, so it may become a new treatment for BPD (Kim et al., 2019).